Olaparide has a significant effect on both castration resistant prostate cancer (CRPC) and ovarian cancer patients with ATM mutation,25, 26 and a multi‐center clinical trial called ORION has been carried out for olaparide in the treatment of advanced NSCLC. This evidence concerns the gene ATM and non-small cell lung carcinoma.